Total Health
J

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 ASCO® Direct Philadelphia

By Total Health FEATURING Jessica Bauman
By Total Health FEATURING Jessica Bauman
368 views
September 29, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
35:40
Balazs Halmos

Year in Review: Lung Cancer

08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
14:49
Vivek Subbiah

Year in Review: Precision Medicine

09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
07:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "KEYNOTE-671 Trial Key Learnings & Cli…

Feat. J. West
16:12
Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
11:50
GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst